Standard
Wake Forest Invests in Postbiotic Ingredient Poised to Combat Age-Related Gut Health Decline
Wake Forest University School of Medicine has made a strategic investment in Postbiotics Inc. (PBI), a move that underscores the growing scientific and commercial interest in postbiotic formulations for addressing age-related gut health challenges. This investment centers on PBI’s exclusive worldwide license for a patented postbiotic ingredient, Lacticaseibacillus paracasei D3.5, which is being marketed under…
